Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy

Completed

Conditions studied: Male Breast Cancer, Neurotoxicity, Peripheral Neuropathy, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer

In brief

This research trial studies heavy metal exposure in predicting peripheral neuropathy in patients with stage I-III breast cancer undergoing chemotherapy. Studying samples of blood and urine in the laboratory for heavy metal exposure from patients receiving chemotherapy may help doctors find out whether side effects from chemotherapy are related to heavy metal exposure.

Key facts

Study ID: NCT01982591
Run by: Fox Chase Cancer Center
People needed: 115
Starts: 2011-01-03
Expected to finish: 2015-03-24
Last updated by the study team: 2017-06-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients must have histologically confirmed invasive mammary carcinoma; any histologic sub-type allowed
Patients must be diagnosed with stage I, II or III breast cancer
Patients must be undergoing treatment with an adjuvant or neoadjuvant cytotoxic chemotherapy that includes a taxane, specifically paclitaxel, nab-paclitaxel (Abraxane), or docetaxel
Patients may have received prior endocrine and/or radiation therapy
Patients must have the ability to understand and the willingness to sign a written informed consent document

You may not qualify if…

Patients who have been previously treated with cytotoxic chemotherapy
Patients with pre-existing peripheral neuropathy

Where it is running

Paoli Memorial Hospital — Paoli, Pennsylvania, United States
Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.